Marinus Pharmaceuticals Inc (MRNS) Position Raised by Granite Point Capital Management L.P.
Granite Point Capital Management L.P. boosted its holdings in shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) by 250.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,684,848 shares of the biopharmaceutical company’s stock after purchasing an additional 1,918,400 shares during the period. Marinus Pharmaceuticals accounts for approximately 3.3% of Granite Point Capital Management L.P.’s holdings, making the stock its 3rd largest holding. Granite Point Capital Management L.P. owned approximately 6.64% of Marinus Pharmaceuticals worth $15,760,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in Marinus Pharmaceuticals during the 3rd quarter valued at $128,000. Citadel Advisors LLC increased its holdings in Marinus Pharmaceuticals by 327.8% during the 3rd quarter. Citadel Advisors LLC now owns 51,383 shares of the biopharmaceutical company’s stock valued at $301,000 after purchasing an additional 39,371 shares in the last quarter. KCG Holdings Inc. increased its holdings in Marinus Pharmaceuticals by 29.5% during the 1st quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 14,692 shares in the last quarter. EAM Investors LLC acquired a new stake in Marinus Pharmaceuticals during the 3rd quarter valued at $554,000. Finally, Jennison Associates LLC boosted its position in Marinus Pharmaceuticals by 108.1% in the 2nd quarter. Jennison Associates LLC now owns 811,665 shares of the biopharmaceutical company’s stock valued at $1,112,000 after buying an additional 421,600 shares during the last quarter. 49.77% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have commented on MRNS shares. ValuEngine lowered Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. JMP Securities reiterated an “outperform” rating and issued a $11.00 price objective (up from $5.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 12th.
Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.02.
Marinus Pharmaceuticals Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Want to see what other hedge funds are holding MRNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Marinus Pharmaceuticals Inc (NASDAQ:MRNS).
Receive News & Stock Ratings for Marinus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.